29.04.2025 • News
Merck & Co. Breaks Ground on $1 Billion Biologics Center in US
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future US home for Keytruda.
Bioprocessing
24.04.2025 • News
Fujifilm Diosynth Biotechnologies & Regeneron Sign Manufacturing Agreement
Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today announced a 10-year manufacturing supply agreement, valued at over $3 billion (€2.64 billion), with Regeneron Pharmaceuticals to provide US-based production of its industry-leading biologic medicines, which treat millions of patients worldwide.
11.04.2025 • News
Asahi Kasei Launches Life Science Division to Boost Bioprocess Innovation
To meet growing demand from the pharmaceutical industry, Asahi Kasei has established Asahi Kasei Life Science to operate its bioprocess businesses under a new organizational structure.
31.03.2025 • News
Seqens and Novonesis Partner for Biocatalytic Processes in Fine Chemicals
The Seqens Group, a global manufacturer of health, personal care, and specialty ingredients, recently announced a strategic partnership with Novonesis, a sustainable biological solutions provider.
11.03.2025 • News
Syngene Acquires its First US Manufacturing Facility
Syngene, a global contract research, development, and manufacturing organization (CRDMO), recently announced the acquisition of its first biologics site in the USA – fitted with multiple monoclonal antibody (mAbs) manufacturing lines.
10.02.2025 • News
Syensqo and Bota Bio Partner on Haircare
Syensqo recently announced a strategic five-year partnership with Bota Bio, a global industrial biotechnology company specializing in biomanufactured, clean, and high-performance consumer products.
11.12.2024 • News
Amgen Plans $1 Billion Manufacturing Expansion in North Carolina
In a move to expand its global biomanufacturing network, US biopharma Amgen is planning to invest $1 billion to build a second drug substance manufacturing facility at its US site in Holy Springs, North Carolina. This brings the company's total planned investment in Holly Springs to more than $1.5 billion, building on its previously announced $550 million commitment.
29.11.2024 • News
Samsung Biologics Signs Manufacturing Deal with European Pharmaceutical Company
Samsung Biologics, a global contract development and manufacturing organization (CDMO), recently announced a series of manufacturing deals with a Europe-based pharmaceutical company.
15.11.2024 • News
Ambiopharm Breaks Ground on $28 Million Expansion
Ambiopharm, a US-based pharmaceutical services company specializing in peptide manufacturing, recently announced the groundbreaking of a 70,000-square-foot (6,504 m2) capacity expansion project at its Shanghai manufacturing site. This $28 million (€26.6 million) project reflects the company’s commitment to serving growing global demand and confidence in China’s vital role in the global pharmaceutical supply chain.
12.11.2024 • News
Lonza to Expand Bioconjugation in Visp, Switzerland
Lonza, a global contract development and manufacturing organization (CDMO) for the pharmaceutical, biotech, and nutraceutical markets, announced today that it will invest in additional bioconjugation capabilities in Visp, Switzerland.
31.10.2024 • News
Sterling Pharma Solutions Expands GMP ADC Manufacturing Capacity
Sterling Pharma Solutions, a global contract development and manufacturing organization (CDMO), today announced the second phase of an expansion strategy at its Deeside, UK site to support antibody-drug conjugate (ADC) development, with a more than £10 million (€11.9 million) investment to increase GMP bioconjugation capacity.
03.10.2024 • News
Lilly Announces New $4.5 Billion Site
Eli Lilly and Company (Lilly) recently announced a $4.5 billion (€4.07 billion) investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development.
24.09.2024 • News
Lonza and Vertex Sign a Commercial Supply Agreement for Casgevy
Lonza and Vertex Pharmaceuticals recently announced a commercial supply agreement for casgevy (exagamglogene autotemcel).
Insights into Biologics and Pharmaceutical Manufacturing
Bill Humphries, CEO of Alcami, shares his vision for the future, discussing dynamic market trends and the company’s commitment to innovation. Under his leadership, Alcami is poised to redefine the pharmaceutical and biotechnology landscape, focusing on cutting-edge solutions and navigating global complexities. This conversation highlights Alcami’s strategic direction, accomplishments, and upcoming challenges.
Minicircle DNA
The minicircle has emerged as a Next Generation Gene Vector and as a promising tool in the field of gene delivery and therapeutic applications. This overview aims to cover the characteristics, production methods, and potential applications of minicircle DNA.
The CDMO/CMO Report
Driven by increased demand in biologic-based drugs, biologic drug substance manufacturing continues to be an active area of investment by contract development and manufacturing organizations/contract manufacturing organizations (CDMOs/CMOs), including several multi-billion large-scale biomanufacturing projects. What companies are expanding, and where do these expansions stand?
09.09.2024 • News
Lonza Completes Expansion of Microbial Manufacturing Facility
Lonza recently announced that it has completed a planned expansion of the mid-scale microbial manufacturing facility at its Visp, Switzerland site. This multi-product facility was recently granted a GMP license, allowing cGMP manufacturing and release of biologics produced using microbial fermentation.
13.08.2024 • News
MSD to Buy B-Cell Depletion Therapy from Curon
Major US drugmaker MSD is to pay up to $1.3 billion to acquire CN201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, from biotechnology company Curon Biopharmaceutical.
24.07.2024 • News
Touchlight and GSK Sign License Agreement for DNA Production
Touchlight, a UK-based custom development and manufacturing organization (CDMO) specializing in enzymatic DNA production, signed a license agreement with British drugmaker GSK which grants GSK non-exclusive rights to use Touchlight’s proprietary enzymatic dbDNA (doggybone DNA) technology for the development and production of mRNA-based products.
23.07.2024 • News
Agilent to Buy Canadian CDMO Biovectra for $925 Million
Santa Clara, CA-based Agilent Technologies has signed a definitive agreement to acquire specialized contract development and manufacturing organization Biovectra from H.I.G. Capital in a move to expand its end-to-end biopharma solutions.
16.07.2024 • News
CordenPharma Invests €900 Million in Peptide Platform Expansion
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform.
13.06.2024 • News
Kyowa Kirin to Establish New Biologics Manufacturing Plant in US
Kyowa Kirin announced a new, state-of-the-art manufacturing facility in Sanford, North Carolina, US. Kyowa Kirin will invest up to $530 million (€489 million) in constructing a 15,951m2 two-bioreactor facility, scheduled to break ground in Q3 of 2024.
05.06.2024 • News
Aurigene Opens Biologics Facility
Aurigene Pharmaceutical Services Limited (Aurigene), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 6500 m2 (70,000 sq ft) in Hyderabad, India.
04.06.2024 • News
Ori Biotech Reveals Automated Platform for Cell & Gene Therapy Production
Ori Biotech a cell and gene therapy (CGT) manufacturing technology producer, recently announced the commercial launch of IRO, a next-generation platform.
31.05.2024 • News
Enzene Launches Drug Discovery Services Division
Enzene Biosciences, a global CDMO announces the launch of a new Drug Discovery Division.
14.05.2024 • News
Sanofi Invests €1 Billion to Boost Drug Manufacturing in France
On Monday, Paris-based French drugmaker Sanofi announced plans to invest more than €1 billion at three facilities in France to create new bioproduction capacity.
14.05.2024 • News
Sartorius and Sanofi Collaborate to Boost Downstream Process Efficiency
Life science group Sartorius and biopharmaceutical firm Sanofi are partnering to create a platform for continuous downstream bioprocessing. Sartorius will use its engineering and manufacturing skills to commercialize integrated and continuous biomanufacturing (ICB) platforms, using Sanofi’s prototypes. In exchange, Sanofi will provide Sartorius with exclusive access to its ICB platform knowledge and patents.
29.04.2024 • Whitepaper
E. Coli Bioprocessing: Pioneering Advances in Biotechnology
Download this complimentary Expert Insights eBook today!
28.03.2024 • News
Aragen Launches First Phase of Biologics Facility in India
Aragen, a CRDMO, has launched the first phase of its biologics manufacturing facility in Bangalore, India. The $30 million project, executed by its subsidiary Aragen Biologics Pvt Ltd, has completed its first small-scale manufacturing project for a US-based organization, producing a novel anticancer monoclonal antibody.
22.03.2024 • News
Afyren Neoxy Gets €3.4 Million in After-Biochem Project
Greentech firm Afyren Neoxy, a subsidiary of Afyren, received a €3.4 million payment this week for achieving key milestones with its bio-based low-carbon products.
21.03.2024 • News
Evonik and Vland Biotech Begin Joint Venture
Evonik Vland Biotech, a new joint venture between Evonik China and Shandong Vland Biotech, began operations on January 1, 2024. The venture aims to expand the market presence of their livestock probiotics in Greater China and develop new products. The official opening took place in Qingdao on March 14.
05.03.2024 • News
Large-Scale Production Announced by Epsilogen and Lonza for Ovarian Cancer Treatment
Epsilogen and Lonza have successfully completed the manufacturing of a potential cancer treatment. The complex process, which took less than ten months, was carried out at Lonza’s UK site following Good Manufacturing Practice (GMP) standards.
26.10.2023 • News
Samsung Biologics Partners with Kurma for Biologics Development and Manufacturing
Samsung Biologics, a global contract development and manufacturing organization (CDMO), and Kurma Partners, a European venture capital firm in healthcare and biotechnology, recently announced a strategic partnership for the development and manufacturing of biologics for Kurma Partners’ portfolio companies.
Biosurfactants at Scale
In response to the urgent need for sustainable solutions in the surfactants industry, companies like Locus Ingredients are developing environmentally friendly biosurfactants.
Quality and Safety in Biopharmaceutical Production
The biopharmaceutical industry is experiencing a drive towards biologic products due to their promise as treatments for chronic diseases.
